FibroBiologics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FBLG | CMMB | ALBPS.PA | FLNA | GRI | XBIT | |
|---|---|---|---|---|---|---|
| Market cap | 6.86M | 9.90M | 19.25M | 27.63M | 3.13M | 59.45M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -41.0 | 0.0 | — | -0.7 | 15.0 |
| Price/book | 1.3 | 1.0 | -0.2 | 0.4 | 0.3 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −85.54% | −55.81% | −62.10% | −80.74% | −97.10% | −18.41% |
| Today | −2.17% | +4.24% | +29.18% | −3.75% | −7.14% | −2.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FBLG news ›[EFFECT] FibroBiologics, Inc. SEC Filing
FibroBiologics, Inc. (FBLG) is a Houston-based clinical-stage biotech developing fibroblast-based cell therapies for chronic diseases across multiple indications. [EFFECT] FibroBiologics, Inc. SEC Filing Sentiment and the balance of points…
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
/PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and... FSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based…
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
PR Newswire Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Me
FibroBiologics closes $1.02M debt financing
The debenture carries 0% annual interest, with scheduled payments starting April 8, 2027 and conversion rights available only after an Event of Default. FibroBiologics, Inc. (FBLG) closed a private placement with Peak One Opportunity Fund,…
FibroBiologics Secures $1.2 Million OID Debenture From Peak One With 125,000 Commitment Shares
TradingView FibroBiologics Secures $1.2 Million OID Debenture From Peak One With 125,000 Commitment Shares FibroBiologics entered into a Securities Purchase Agreement with Peak One to issue a $1.2 million
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
New approach proposes an alternative to repeated injections Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills. FibroBiologics is developing a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net6
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.